Anixa Biosciences, Inc. (ANIX) News
Follow Anixa Biosciences, Inc. (ANIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: Phase 1 survival gains and HC Wainwright trims target to $6
Anixa Biosciences, Inc. (NASDAQ:ANIX) reported preliminary Phase 1 lira—cel data showing several ovarian cancer patients survived past one year as the trial continues to monitor safety and efficacy, while HC Wainwright t
NEWS | Sep 28, 2026, 11:06 AM UTC
L
ANIX - Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
ANIX - Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
NEWS | Sep 21, 2026, 12:46 PM UTC
L
ANIX - Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
ANIX - Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
NEWS | Sep 16, 2026, 01:16 PM UTC
L
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 9 at 08:43 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, conta
EARNINGS | Sep 09, 2026, 08:43 PM UTC
L
Anixa Biosciences reports Q3 net loss, no revenue
Anixa Biosciences reported a third-quarter 2026 net loss attributable to common shareholders of $(2.61M) and diluted loss per share of $(0.08). Revenue was $0, and the company said it continued development work on oncolo
EARNINGS | Sep 09, 2026, 08:23 PM UTC
L
ANIX reports net loss narrowed and $13.9 million cash
ANIX said its net loss narrowed year-over-year as R&D and G&A expenses declined. The company reported cash and investments of $13.9 million expected to fund operations for at least twelve months, with clinical progress i
EARNINGS | Sep 09, 2026, 08:19 PM UTC
L
ANIX - Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
ANIX - Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
EQUITY | Sep 09, 2026, 12:35 PM UTC
L
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Previous quarterly performance (using preferred earnings measure in US dollars). This summary was machine generated September 4 at 20:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning
EARNINGS | Sep 04, 2026, 08:05 PM UTC
L
Anixa Biosciences to present at Nasdaq & LD Micro SF Summit on Sept. 9
Anixa Biosciences (ANIX) plans to present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026.
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Anixa Biosciences to present at Cantor healthcare conference
Anixa Biosciences will present at the 2026 Cantor Fitzgerald Global Healthcare Conference, highlighting its breast cancer vaccine and ovarian cancer CAR-T therapy.
EQUITY | Aug 24, 2026, 12:55 PM UTC
L
Anixa Biosciences to Present at H.C. Wainwright 28th Annual Conference
Anixa Biosciences (ANIX) will present at the H.C. Wainwright 28th Annual Global Investment Conference, according to the company announcement.
EQUITY | Aug 18, 2026, 12:45 PM UTC
L
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial
() -- Anixa Biosciences (ANIX) said Monday the first patient has been treated in the fifth cohort of its phase 1 trial evaluating its novel CAR-T therapy lira-cel, which targets follicle stimulating hormone receptor for
EQUITY | Jul 06, 2026, 01:02 PM UTC
H
ANIX Reports Positive Trial Data
Anixa Biosciences reports positive data from breast cancer vaccine phase 1 trial and CAR-T phase 1 trial
EQUITY | Jun 26, 2026, 01:11 PM UTC